---
title: IMpassion132 double-blind randomised phase III trial of chemotherapy with or
  without atezolizumab for early relapsing unresectable locally advanced or metastatic
  triple-negative breast cancer
date: '2024-05-16'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38755096/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240517181955&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'CONCLUSIONS: OS, which is dismal in patients with TNBC relapsing within
  <12 months, was not improved by adding atezolizumab to chemotherapy. A biology-based
  definition of intrinsic resistance to immunotherapy in aTNBC is urgently needed
  to develop novel therapies for these patients in next-generation clinical ...'
disable_comments: true
---
CONCLUSIONS: OS, which is dismal in patients with TNBC relapsing within <12 months, was not improved by adding atezolizumab to chemotherapy. A biology-based definition of intrinsic resistance to immunotherapy in aTNBC is urgently needed to develop novel therapies for these patients in next-generation clinical ...